GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Pretax Margin %

HQL (abrdn Life Sciences Investors) Pretax Margin % : 98.87% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. abrdn Life Sciences Investors's Pre-Tax Income for the six months ended in Mar. 2024 was $50.26 Mil. abrdn Life Sciences Investors's Revenue for the six months ended in Mar. 2024 was $50.83 Mil. Therefore, abrdn Life Sciences Investors's pretax margin for the quarter that ended in Mar. 2024 was 98.87%.

The historical rank and industry rank for abrdn Life Sciences Investors's Pretax Margin % or its related term are showing as below:

HQL' s Pretax Margin % Range Over the Past 10 Years
Min: 95.02   Med: 98.24   Max: 101.64
Current: 97.13


HQL's Pretax Margin % is ranked better than
65.21% of 1673 companies
in the Asset Management industry
Industry Median: 91.08 vs HQL: 97.13

abrdn Life Sciences Investors Pretax Margin % Historical Data

The historical data trend for abrdn Life Sciences Investors's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Pretax Margin % Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Pretax Margin %
Get a 7-Day Free Trial 101.64 99.17 98.24 101.31 95.02

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.84 102.59 98.26 105.25 98.87

Competitive Comparison of abrdn Life Sciences Investors's Pretax Margin %

For the Asset Management subindustry, abrdn Life Sciences Investors's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's Pretax Margin % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Pretax Margin % falls into.



abrdn Life Sciences Investors Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

abrdn Life Sciences Investors's Pretax Margin for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=22.352/23.524
=95.02 %

abrdn Life Sciences Investors's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=50.256/50.831
=98.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


abrdn Life Sciences Investors  (NYSE:HQL) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


abrdn Life Sciences Investors Pretax Margin % Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
Kathleen Goetz director 1310 OAK VALLEY CIRCLE, POLK CITY IA 50226
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103

abrdn Life Sciences Investors Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-16-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 01-06-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Declares Cash Distribution

By Business Wire Business Wire 12-22-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-16-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 09-30-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2022